Abstract:Background Diagnosis of colorectal cancer (CRC) during early stages can greatly improve patient outcome. Although technical advances in the field of genomics and proteomics have identified a number of candidate biomarkers for non-invasive screening and diagnosis, developing more sensitive and specific methods with improved cost-effectiveness and patient compliance has tremendous potential to help combat the disease. Methods We enrolled three cohorts of 479 subjects, including 226 CRC cases, 197 healthy controls, and 56 advanced precancerous lesions (APC). In the discovery cohort, we used quantitative mass spectrometry to measure the expression profile of plasma proteins and applied machine-learning to select candidate proteins. We then developed a targeted mass spectrometry assay to measure plasma concentrations of seven proteins and a logistic regression classifier to distinguish CRC from healthy subjects. The classifier was further validated using two independent cohorts. Results The seven-protein panel consisted of leucine rich alpha-2-glycoprotein 1 (LRG1), complement C9 (C9), insulin-like growth factor binding protein 2 (IGFBP2), carnosine dipeptidase 1 (CNDP1), inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3), serpin family A member 1 (SERPINA1), and alpha-1-acid glycoprotein 1 (ORM1). The panel classified CRC and healthy subjects with high accuracy, since the area under curve (AUC) of the training and testing cohort reached 0.954 and 0.958. The AUC of the two independent validation cohorts was 0.905 and 0.909. In one validation cohort, the panel had an overall sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 89.9%, 81.8%, 89.2%, and 82.9%, respectively. In another blinded validation cohort, the panel classified CRC from healthy subjects with a sensitivity of 81.5%, specificity of 97.9%, and overall accuracy of 92.0%. Finally, the panel was able to detect APC with a sensitivity of 49%. Conclusions This seven-protein classifier is a clear improvement compared to previously published blood-based protein biomarkers for detecting early-stage CRC, and is of translational potential to develop into a clinically useful assay.

Plasma Choline-Containing Phospholipids: Potential Biomarkers for Colorectal Cancer Progression

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-Of-Flight Mass Spectrometry-Based Metabolic Profiling of Human Serum Prior to and Following Radical Resection of Colorectal Carcinoma

A plasma lipidomics strategy reveals perturbed lipid metabolic pathways and potential lipid biomarkers of human colorectal cancer.

Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers

A Conjunctive Lipidomic Approach Reveals Plasma Ethanolamine Plasmalogens and Fatty Acids As Early Diagnostic Biomarkers for Colorectal Cancer Patients

Identification of Phosphatidylcholine and Lysophosphatidylcholine As Novel Biomarkers for Cervical Cancers in a Prospective Cohort Study

Serum Unsaturated Free Fatty Acids: A Potential Biomarker Panel for Early-Stage Detection of Colorectal Cancer.

LC-MS-based Lipid Profile in Colorectal Cancer Patients: TAGs Are the Main Disturbed Lipid Markers of Colorectal Cancer Progression.

Plasma Levels of Microrna-24, Microrna-320A, and Microrna-423-5p Are Potential Biomarkers for Colorectal Carcinoma

A Proteomic Classifier Panel for Early Screening of Colorectal Cancer: a Case Control Study

Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection

Exploration of the application potential of serum multi-biomarker model in colorectal cancer screening

Plasma DNA Integrity As a Prognostic Biomarker for Colorectal Cancer Chemotherapy

Comprehensive serum proteomics profiles and potential protein biomarkers for the early detection of advanced adenoma and colorectal cancer

Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma

Plasma Mir-601 And Mir-760 Are Novel Biomarkers For The Early Detection Of Colorectal Cancer

Plasma Micrornas Are Promising Novel Biomarkers for Early Detection of Colorectal Cancer

A Plasma Microrna Panel for Early Detection of Colorectal Cancer

UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer

Simultaneous Quantification of Serum Multi-Phospholipids As Potential Biomarkers for Differentiating Different Pathophysiological States of Lung, Stomach, Intestine, and Pancreas.